TP53 and neoplasm: PDMP treatments dramatically decreased CSCs, by more than twofold (4.9% vs. 1.9% of total tumor cells, p<0.001) in TP53 tumors treated with PDMP combined doxorubicin, but not in SW48 tumors (Figure 7A).